The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hormone Refractory Prostate Cancer (HRPCA) Market Research Report 2025
Synopsis
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer (HRPCA).
Report Scope
The Hormone Refractory Prostate Cancer (HRPCA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Prostate Cancer (HRPCA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Prostate Cancer (HRPCA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer (HRPCA).
Report Scope
The Hormone Refractory Prostate Cancer (HRPCA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Prostate Cancer (HRPCA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Prostate Cancer (HRPCA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cytotoxic Agents
1.2.3 Anti-Androgens
1.2.4 Vaccines
1.2.5 Radio-Pharmaceuticals
1.3 Market by Application
1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2019-2030)
2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Region
2.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Region (2019-2024)
2.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2025-2030)
2.3 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
2.3.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
2.3.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
2.3.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue
3.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2019-2024)
3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2019-2024)
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio
3.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2023
3.5 Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
3.7 Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Type
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2019-2024)
4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2025-2030)
5 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Application
5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2019-2024)
5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2019-2030)
6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024)
6.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2019-2030)
7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024)
7.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2019-2030)
8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2019-2024)
8.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2019-2030)
9.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024)
9.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2019-2030)
10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024)
10.4 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Inc
11.1.1 Astellas Inc Company Detail
11.1.2 Astellas Inc Business Overview
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
11.1.5 Astellas Inc Recent Development
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Detail
11.2.2 Sanofi S.A Business Overview
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
11.2.5 Sanofi S.A Recent Development
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Detail
11.3.2 Dendreon Corporation, Bayer AG Business Overview
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
11.3.5 Dendreon Corporation, Bayer AG Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Cytotoxic Agents
Table 3. Key Players of Anti-Androgens
Table 4. Key Players of Vaccines
Table 5. Key Players of Radio-Pharmaceuticals
Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2019-2024)
Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2025-2030)
Table 12. Hormone Refractory Prostate Cancer (HRPCA) Market Trends
Table 13. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
Table 14. Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
Table 15. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
Table 16. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players (2019-2024)
Table 18. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2023)
Table 19. Ranking of Global Top Hormone Refractory Prostate Cancer (HRPCA) Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
Table 23. Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2019-2024)
Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2025-2030)
Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2019-2024)
Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2025-2030)
Table 33. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2025-2030) & (US$ Million)
Table 48. Astellas Inc Company Detail
Table 49. Astellas Inc Business Overview
Table 50. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product
Table 51. Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024) & (US$ Million)
Table 52. Astellas Inc Recent Development
Table 53. Sanofi S.A Company Detail
Table 54. Sanofi S.A Business Overview
Table 55. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product
Table 56. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024) & (US$ Million)
Table 57. Sanofi S.A Recent Development
Table 58. Dendreon Corporation, Bayer AG Company Detail
Table 59. Dendreon Corporation, Bayer AG Business Overview
Table 60. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product
Table 61. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024) & (US$ Million)
Table 62. Dendreon Corporation, Bayer AG Recent Development
Table 63. Johnson & Johnson Company Detail
Table 64. Johnson & Johnson Business Overview
Table 65. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product
Table 66. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024) & (US$ Million)
Table 67. Johnson & Johnson Recent Development
Table 68. Research Programs/Design for This Report
Table 69. Key Data Information from Secondary Sources
Table 70. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type: 2023 VS 2030
Figure 3. Cytotoxic Agents Features
Figure 4. Anti-Androgens Features
Figure 5. Vaccines Features
Figure 6. Radio-Pharmaceuticals Features
Figure 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Specialty Clinics Case Studies
Figure 12. Others Case Studies
Figure 13. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region: 2023 VS 2030
Figure 17. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players in 2023
Figure 18. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2023
Figure 20. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2019-2030)
Figure 22. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2019-2030)
Figure 26. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2019-2030)
Figure 34. China Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2019-2030)
Figure 42. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2019-2030)
Figure 46. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
Figure 49. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
Figure 50. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
Figure 51. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2019-2024)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
